Thermo Fisher Scientific launches fully automated test to tell
IBS from IBD
19 January 2012
Thermo Fisher Scientific Inc. has announced the availability
of EliA Calprotectin, the first fully automated test for faecal
calprotectin. The test can differentiate inflammatory bowel diseases
(IBD) such as Crohn‘s disease and ulcerative colitis from irritable
bowel syndrome (IBS) and other functional bowel disorders (BD).
The test, which can be run on Phadia instruments available from
Thermo Fisher, offers high specificity, high sensitivity and
excellent predictive values to assist clinicians with early
“Today's tighter medical budgets require laboratories to become
more efficient without compromising accuracy or negatively impacting
patient care,” said Michael Haass. “By using the EliA Calprotectin
test, labs can enable faster and more accurate diagnosis than
standard tests currently used to distinguish IBD from IBS, and this
ultimately delivers faster relief to patients in need.”
A faecal calprotectin test is highly effective in discriminating
IBD from IBS and in helping monitor disease activity following
diagnosis. It can also predict a relapse during clinical remission.
The test has been shown to outperform blood tests such as CRP or ESR
in discrimination and is effective in reducing the number of
inconvenient and expensive endoscopic procedures.
Phadia AB, now part of Thermo Fisher Scientific, develops,
manufactures and markets complete blood test systems to support the
clinical diagnosis and monitoring of allergy, asthma and autoimmune
disease. Its mission is to dramatically improve the management of
allergy, asthma and autoimmune diseases by providing healthcare
professionals with superior diagnostic technologies and clinical
expertise. For more information, visit www.phadia.com.
Source: Thermo Fisher